Bausch + Lomb announced top-line results from its phase 2 study evaluating BL1107 in patients with glaucoma. The study did not achieve its primary endpoint of replicating visual function improvements observed in a smaller phase 1/2a study following 28 days of topical administration. Based on the totality of the data, the company has decided not to advance the program in this indication as a topical eye drop, Bausch + Lomb said in a press release. 

The randomized, double-masked, 3-arm, parallel-group study enrolled 159 adults aged 18 and older with primary open-angle glaucoma or ocular hypertension. The study did not meet its primary endpoint, defined as change from baseline in visual field mean deviation at day 28 (exit, hour 2). Key secondary endpoints assessing visual function, including low-luminance best-corrected visual acuity responder rates, were also not achieved. Evidence of ocular target engagement was observed, as demonstrated by meeting a secondary endpoint of a reduction in intraocular pressure at day 28 (exit, hour 2). The safety profile was consistent with prior clinical experience with BL1107, with no new safety signals identified, the company said.

Bausch + Lomb acquired Whitecap Biosciences in 2025 primarily for the promise of developing a sustained-release implant for the treatment of geographic atrophy (GA). BL1107 (originally referred to as WB007) also showed positive clinical results—with a small sample size—for improving visual acuity in glaucoma patients. The company said it made a strategic decision to pursue both indications and will now focus solely on developing the first small-molecule sustained-release implant for GA. Bausch + Lomb said it expects clinical trials to begin in 2028 and will continue to collaborate on the candidate with Ripple Therapeutics, whose patented technology platform is based on a discovery that drugs can be chemically engineered into controlled-release pharmaceuticals without the use of polymers.